Clinical Trials Logo

Viral Pneumonia clinical trials

View clinical trials related to Viral Pneumonia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06349707 Not yet recruiting - Viral Pneumonia Clinical Trials

Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic

VirCoV+
Start date: April 2024
Phase:
Study type: Observational

The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge.

NCT ID: NCT06348095 Not yet recruiting - Viral Pneumonia Clinical Trials

Effect of Probiotics on Viral Pneumonia

Start date: May 7, 2024
Phase: N/A
Study type: Interventional

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with viral pneumonia, in comparison with placebo.

NCT ID: NCT05612893 Not yet recruiting - Sepsis Clinical Trials

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

DISPLAY
Start date: November 16, 2022
Phase:
Study type: Observational

The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia

NCT ID: NCT05286255 Not yet recruiting - COVID-19 Pneumonia Clinical Trials

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

SAMPSON-1
Start date: September 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.

NCT ID: NCT04955223 Not yet recruiting - Viral Pneumonia Clinical Trials

Yinhu Qingwen Granule in the Treatment of Viral Pneumonia

Start date: December 2022
Phase: Early Phase 1
Study type: Interventional

This is a non-randomized single arm clinical study to observe the effect of Yinhu Qingwen Granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

NCT ID: NCT04876573 Not yet recruiting - COVID-19 Pneumonia Clinical Trials

Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Pilot study for evaluating the feasibility, security and efficacy of the use of Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized treatment in a population of patient who are hospitalized and requiring oxygen therapy for COVID-19.

NCT ID: NCT04820751 Not yet recruiting - Clinical trials for Platelet Dysfunction

Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

Start date: April 10, 2021
Phase: Phase 3
Study type: Interventional

This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.

NCT ID: NCT04397497 Not yet recruiting - Covid-19 Clinical Trials

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

COMBAT-19
Start date: May 22, 2020
Phase: Phase 2
Study type: Interventional

This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab or placebo, in addition to standard of care per local practice. The total trial duration will be 12 weeks after single mavrilimumab or placebo dose.